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SUMMARY – Oral melanoma (OM) occurs from activated or genetically altered epidermal me-
lanocytes. Th ere is no scientifi c evidence that OM can be linked to physical, chemical and thermal 
irritation, or to other risk factors of the oral cavity. According to fi gures from various countries, OM 
accounts for 0.2% to 7.5% ( Japan) of all cases of melanoma of the skin and mucous membrane. Th e 
male to female ratio of OM is 2:1. About 80% of OMs are located in the mucosa of the palate and 
maxillary gingiva. Th is paper presents two cases of oral mucosal melanoma of the upper and lower lips 
in women aged 62 and 59 years. Diagnosis, diff erential diagnosis and therapy are reported.
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Introduction
Melanoma as a malignant lesion can occur from 
activated or genetically altered epidermal melanocytes. 
Activation of melanocytes is a result of complex inter-
actions among genetic, constitutional and environ-
mental factors1. In contrast to skin melanoma, the eti-
ology of which in most cases is related to ultraviolet 
light, this risk factor does not exist for oral melanoma 
(OM). Th ere is no scientifi c evidence that OM can be 
linked to physical, chemical and thermal irritation, or 
to other risk factors in the oral cavity, for example, al-
cohol, poor oral hygiene, caries and damaged teeth, 
prosthetics and other irritations to which oral cavity is 
constantly exposed. Formaldehyde and smoking are 
listed as risk factors. In workers professionally exposed 
to formaldehyde fumes, cases of sinonasal melanomas 
have been reported2. Swedish authors mention the 
more prevalent pigmentation of oral mucosa in smok-
ers, deeming it to be a risk factor for OM3. Knowledge 
of the etiology of OM comes mainly from epidemio-
logical studies, but these risk factors for OM have not 
been confi rmed by scientifi c evidence. It is thought 
that after dysplastic nevus, as a precursor, some OMs 
occur de novo4. Th e physiological accumulation of mel-
anin pigmentation in melanocytes is manifested clini-
cally in a variety of effl  orescence on the skin, mainly 
moles and freckles. When melanin is formed and ac-
cumulated in melanocytes with malignant characteris-
tics, melanomas occur. Melanomas may develop from 
preexisting pigmentation of the skin and mucosa, but 
some occur de novo.
For melanomas of the head and neck, Virag lists 
three types and gives their quantifi cation5. Th ey are: su-
perfi cial spreading melanoma (SSM), which occurs in 
about 70% of patients; nodular malignant melanoma 
(NM), which occurs in about 15% of patients; and len-
tigo maligna melanoma (LMM), which occurs in about 
15%, in older patients, on the exposed parts of the body 
on the basis of premalignant melanosis as the result of 
chronic exposure to sunlight; according to the personal 
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clinical experience of Professor Virag, acral melanomas 
do not occur on the skin of the head and neck5.
Melanomas of the skin are located in the area of 
the face and the front of the hair, accounting for most 
melanomas of the face and neck, and are related to 
lymph nodes in the parotid region6. In the superfi cial 
lobe of the parotid gland, there are 2 to 10 lymph 
nodes, but half as many nodes lie medially to the facial 
nerve. Surgery of the parotid gland is complicated by 
the facial nerve and its branches (pes anserinus). Sur-
gery of the parotid is said to be in fact surgery of the 
facial nerve7. Facial nerve has an important functional, 
aesthetic, operational, communication and social value.
Th e microscopic spread of melanoma develops in 
two directions, i.e. horizontally, radially (mainly relat-
ed to the epidermis), and vertically, invasively (related 
to deeper structure of the skin and mucosa, dermis, 
subcutis, blood and lymph vessels)8.
Th e degree of invasiveness of a skin melanoma is 
determined histopathologically, using the Breslow9 or 
Clark10 criteria.
Breslow proposees direct measurement of tumor 
thickness using calibrated ocular micrometer. Th e 
maximum vertical diameter of the tumor is evaluated, 
which represents the distance from the tip of the gran-
ulated layer of the epidermis and deepest point of tu-
mor cell infi ltration, and if the lesion is ulcerated, then 
from the base of the ulcer to the deepest point of tu-
mor invasion. According to this criterion, there are 4 
stages of invasiveness9. Th e Clark criteria have fi ve 
stages of invasiveness10.
Characteristics of Oral Melanomas
In contrast to the skin, it is more diffi  cult to dif-
ferentiate by microscope the papillary layer from the 
reticular layer in the oral mucosa, which means that 
the Clark criteria are not applicable for oral mucosa. 
Routine diagnostics of the depth or thickness of tu-
mors, as defi ned by Clark and Breslow, has not been 
accepted in everyday practice for OM, due to these 
structural diff erences between the skin and the oral 
mucosa. For example, fi ve-year survival with gingival 
melanoma was 18%, and with melanoma of the palatal 
mucosa 11%11. Most melanomas of the mucosa of the 
head and neck at the time when they are presented, 
are in stage I. Prasad et al.12 defi ned this status using a 
3-level micro-staging system, which represents diff er-
ent micro-anatomic spaces of the separate tissue barri-
ers. Th ese are a signifi cant predictor related to 5-year 
survival12,13. Th e American Joint Committee on Cancer 
(AJCC) Melanoma Staging Committee, in its already 
existing guide to melanoma, updated the criteria in the 
fi nal version of the Tumor-Node-Metastasis (TNM) 
classifi cation of melanoma14. However, in this updated 
version of the TNM classifi cation of melanomas, the 
AJCC did not defi ne criteria for mucosal melanomas 
because no universal staging system exists for them. 
Diff erent staging systems are in use for diff erent ana-
tomic locations15. In the assessment of oral mucosal 
melanomas, a simplifi ed system is used including three 
stages, as follows: stage I, primary localization of dis-
ease; stage II, primary disease with metastasis to cervi-
cal lymph nodes; and stage III, distant metastasis8.
As already mentioned, in stage I, a 3-level micro-
staging system has been defi ned, where each level rep-
resents a micro-anatomic space, defi ned by tissue 
boundary. Destruction of any barrier (boundary) of 
that space correlates with progressive deterioration of 
survival rates. Stage I has 3 levels: Level 1, in situ mu-
cosal melanoma or microinvasion: Level 2, invasion 
restricted to the lamina propria; and Level 3, melano-
ma with deep invasion into the neighboring tissue, 
such as bone (in the oral mucosa), cartilage (in the lar-
ynx), or skeletal muscle12,13.
Th e superfi cial architecture of oral melanomas is 
seen in macular, ulcerous or nodular forms.
According to the recommendation by the Western 
Society of Teachers of Oral Pathology (WESTOP) 
Banff  Workshop, oral malignant melanomas should be 
considered separately from skin melanomas and sub-
classifi ed according to the histopathologic picture as in 
situ melanomas; invasive melanomas; combined: inva-
sive melanomas with in situ components; and atypical 
melanocyte proliferation, in cases where there is an 
equivocal histologic diagnosis16.
Japanese and Mexican authors suggest that OM 
diff ers from skin melanoma from the point of view of 
the clinical picture, etiology and malignancy. Th ey pro-
pose 5 types of OM for the clinical picture: pigmented 
nodular type; non-pigmented nodular type; pigment-
ed macular type; pigmented mixed type; and non-pig-
mented mixed type17,18.
Clinical verifi cation of OM meets the ABCDE 
rules from the Anglo-Saxon and German dermatology 
literature: A, asymmetry; B, border irregularity; C, 
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color variation; D, diameter >6 mm; and E, eleva-
tion19-21.
Th is typical clinical characterization of melanomas 
has been extended by Šitum et al.22 from ABCDE to 
ABCDEFG, which is used in professional work and 
self-examinations. ABCDE have the same character-
istic as above, followed by: F, feeling, itch, burn or pain; 
and G, growth, increasing size22.
A combination of these signs and symptoms arous-
es suspicion of a melanoma. It would be desirable to 
use characteristics in a fl ier, with photographs for 
health education related to suspicion of melanomas.
Oral melanomas begin in the early phases as patchy 
brown or black blisters of irregular shape, which grow 
or develop into diff use or nodular formations with fo-
cal points in hyper- and hypopigmentation, ulceration, 
bleeding, pain or loss of teeth (gingival location). 
Spotty or satellite lesions may appear around an OM, 
as on the skin23-25. Th ey are a sign of already advanced 
melanoma, and are often accompanied by metastases 
to cervical lymph nodes. Melanomas of the oral cavity 
are located in 80% of cases on the mucosa of the palate 
and gingiva, and in other parts of the oral cavity, e.g., 
buccal mucosa, lips, tongue, base of the mouth, and 
uvula in 20% of cases4,26,27. From 35% to 37% of pa-
tients in whom OM develops, have pre-existing be-
nign melanomatosis of the oral mucosa28. Th e presence 
of asymptomatic oral pigmentation at the site of an 
OM is on average discovered before diagnosis, in one-
third of patients. Th ese asymptomatic pigmentations 
may be the beginning of the radial phase of develop-
ment of a tumor and are often unrecognized by the 
physician and patient. Th is phase may last for months 
or even years, until the signs of a tumor or tumor inva-
sion appear. Th e absence of problems frequently causes 
patients to delay seeking medical care29.
Diff erential Diagnosis of Oral Melanomas
Pigmentations of oral mucosa in terms of mor-
phology may be solitary (focal), multiple or diff use, 
and in terms of origin they are non-melanocytic and 
melanocytic30. Non-melanocytic pigmentations are 
tattoos, amalgam, medicament, heavy metals, lingua 
villosa nigra, and hemochromatosis. Melanocytic pig-
mentations are physiological (racial), ephelides (spots), 
smoker’s melanosis, in systemic diseases, oral mela-
notic macule and palpable pigmented lesions (oral ma-
lanoacanthoma, nevi – moles and oral malignant mela-
nomas). Amelanotic oral melanomas are a particular 
problem, that is melanomas that occur de novo29.
Methods in the Diagnosis of Melanomas
After a detailed family and personal history is tak-
en, a very thorough clinical examination is conducted. 
Every pigmented change of the oral mucosa for which 
the precise cause is not known is suspect in terms of 
diff erential diagnosis for potential melanoma, and it 
must be diagnosed by histopathology. Histopathologic 
diagnosis is the gold standard in the diagnosis of mela-
nomas.
Morphological examination of biopsy samples, 
stained using the standard hematoxylin-eosin (HE) 
method, is essential for setting the histopathologic di-
agnosis. Th e parameters evaluated by microscope in-
clude assessment of the following: presence of absence 
of melanocytes in the tumor (melanocytic or non-me-
lanocytic tumor); cell morphology (epithelioid, spin-
dle, plasmacytoid or mixed); form of cell organization 
(solid, alveolar, organoid or pagetoid); presence of ne-
crosis, and perineural and perivascular invasion; and 
depth of tumor invasion, cell invasion according to the 
criteria of Prasad et al.12 divided into: (a) noninvasive 
(in situ), (b) microinvasive (fi rst level in which tumor 
cells are present in the superfi cial part of lamina pro-
pria), (c) invasive (second level with tumor cells in the 
lamina propria), and (d) deeply invasive (third level 
where the invasion extends into the muscle, bone or 
cartilage).
Oral melanoma is a relatively rare neoplasm with 
poor prognosis, and the non-melanocytic type has 
even worse prognosis, in view of the fact that it is bio-
logically more aggressive and harder to diagnose, 
which makes treatment of lesions more often pro-
longed. Conventional morphological analysis in many 
cases is not suffi  cient, and it is complemented with 
some other techniques, such as histochemistry (e.g., 
Periodic Acid Schiff  (PAS) and Fontana stains) and 
more recently immunohistochemistry (IHC). IHC is 
a diagnostic method that is today widely used in histo-
pathology, in view of its diagnostic, prognostic, and 
recently also theranostic importance. IHC allows visu-
alization of specifi c cell or tissue macromolecules from 
the globulin group (designated as immunoglobins, an-
tigens or immunogens). Th e antigen-antibody reac-
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tion, which is the basis of immunology, has found wide 
application in this method, which is performed in situ 
in human cells or tissues. Th e basis of this method is 
mutual affi  nity between antigens (epitope) and anti-
bodies (paratope). Th e reaction is reversible because it 
is not based on the creation of chemical bonds. Visual-
ization of the Ag-At bond is made using staining, that 
is, a chromogen, which does not change the biologic 
activity of the antibody. Th e most frequently used 
chromogen is 3,3’-diaminobenzedine (DAB) which 
stains the end product of the reaction brown, or 3-ami-
no-9-ethylcarbazole which gives the end product of 
the reaction a red color.
Alongside IHC there is routine histopathologic di-
agnosis, molecular pathology methods are also used, 
which still cannot replace traditional morphological 
analysis, but can make signifi cant contribution to cor-
rect establishment of the defi nitive histopathologic 
diagnosis.
Since OM cells may have an extremely polymor-
phic appearance (epithelioid, spindle or plasmocytoid) 
and this type of malignoma shows a wide morpho-
logical spectrum, and lesions may resemble epithelial, 
histologic, mesenchymal and neural tumors, the use of 
IHC in establishing defi nitive diagnosis is of great as-
sistance. Th e most frequently used antibodies that re-
act with melanocyte proteins are HMB-45, Melan A 
and protein S-100. HMB-45 is a 35-kDa glycoprotein 
melanosome and is a marker of activated melanocytes, 
so it is used in the diagnosis of melanomas. It is a very 
sensitive, but slightly less specifi c melanocyte marker, 
in view of the fact that it sometimes shows expression 
in some other cell types. It can show zonal intra-tumor 
variations in the intensity of staining.
Th e Melan-A protein is a product of the MART-1 
gene and is specifi c for melanocyte cells, and thus also 
for the lesions which develop from them. It is also a 
less specifi c protein, in view of the fact that it is also 
found in some other cell types, that is, benign and ma-
lignant tumors of the adrenocortical region, tumors of 
the testicles with their origin in Leydig cells, as well as 
ovarian tumors originating from Sertoli and Leydig 
cells.
Protein S-100 is a 21-kDa protein of high sensitiv-
ity (97%-100%) and less specifi city for melanocytes, 
since its expression is possible in lipocytes, chondro-
cytes, macrophages, and Langerhans and dendritic 
cells. Reduction in expression or loss of expression may 
occur in the zones of melanoma with strong necrosis. 
Protein S-100, besides helping in determining tumor 
thickness, has been shown in some studies to be of a 
potential prognostic value, i.e. the intensity of staining 
by protein S-100 was in reverse correlation with the 
survival time31-33.
All these routinely and most frequently used anti-
bodies in the histopathologic diagnosis of OM are 
used in cases of melanocytic diff erentiation of tumor 
cells, i.e. in diff erentiating melanocytes from some 
other types of non-melanocytic malignant cells they 
resemble (e.g., cells of undiff erentiated carcinomas, 
lymphomas), in visualization of occult tumor cells, as-
sessment of the depth of tumor invasion, and in detec-
tion of metastasis. IHC is useful in the assessment of 
distribution-density, number and cytoarchitecture (de-
gree of atypia) of the lines of the lesion.
Immunohistochemistry is not an absolutely sover-
eign diagnostic method; it is a very good auxiliary 
method, which is used abundantly in routine, espe-
cially in oncologic diagnosis. It cannot and must not 
replace traditional morphological diagnosis. IHC is an 
important but not obligatory diagnostic procedure. 
Immunohistochemical and molecular pathology 
methods are also used, which still cannot replace tradi-
tional morphological analysis, but can make signifi -
cant contribution to correct establishment of the de-
fi nitive histopathologic diagnosis.
In the diagnosis of OM, the following may also be 
used: computed tomography (CT); magnetic reso-
nance imaging (MRI); and positron emission tomog-
raphy (PET) which can hardly diff erentiate melanoma 
from nevus, but in combination of PET/CT it has di-
agnostic value8.
Treatment of Melanomas
Treatment of OM primarily presumes surgical re-
moval of the tumor, with or without neck dissection. 
Th at is to say, the region of the head is the anatomi-
cally most complex part of the human body, where in a 
small area there are vital organs, osteomuscular and 
blood vessel structures, and nerves, but no less impor-
tant is to point out that in this region there is the most 
dense network of lymphatic vessels and the greatest 
number of lymph nodes. Due to the latter, the possi-
bility of metastasis of melanoma localized on the head 
(and mucosa) is also greater than on the skin of the 
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body. Moreover, this fact is important in planning sur-
gical procedure. It is no less important to point out 
that it is also a prominent localization, where the ex-
tent of the intervention involves mutilation and mal-
formations that cannot be concealed. Th e skill of the 
surgeon, good planning of the procedure, and surgical 
technique are extremely important, not only for thera-
peutic reason, but also for the patient quality of life34.
Treatment of OM consists of surgical removal of 
the tumor, with or without neck dissection.
Adjuvant therapy is also administered, which in-
cludes radiotherapy, chemotherapy, immunotherapy 
and immunomodulators35.
Case Report 1
Th e patient B. E., a female aged 62, was admitted 
to the Clinical Department of Maxillofacial Surgery, 
Sarajevo University Hospital Centre, on April 16, 
2007, due to tumorous changes in the region of the 
upper lip. Th e changes had been present for the previ-
ous 6 months as verrucous lesions and darker pigmen-
tation, which were painless, with a tendency for grad-
ual growth, and occasional spontaneous bleeding (Fig. 
1). Her detailed medical history included no previous 
hospitalization, hereditary ailments, or allergies to 
food or medication. She took Lopril 1x5 mg as therapy 
and Apaurin when necessary. She was a nonsmoker, 
and did not consume alcohol. Clinical examination 
verifi ed melanocytic changes localized on the mucosa, 
also aff ecting the angular part of the upper lip in the 
medial line, 2.5x2.5 cm in diameter, with regular edges, 
slightly raised above the level of the surrounding mu-
cosa and skin. Th e regional lymph nodes were not pal-
pable. Surgical excision of the changes and primary 
reconstruction of the defect using a localized fl ap was 
performed. Th e histopathology results indicated Mela-
noma nodulare malignum mucosae labii superior (Clark 
4, Breslow 1.7 mm, T2b). After this, the patient was 
followed-up by the oncology consultant with regular 
examinations of the neck, abdomen and lung x-ray ev-
ery six months.
In September 2011, due to bilateral neck lymph-
adenopathy, the patient was admitted to the hospital 
again. Bilateral supraomohyoid neck dissection was 
performed, and the histopathology results indicated 
regional dissemination of the disease. As part of the 
oncologic treatment, chemotherapy was administered 
(DTIC, dacarbazine), and the patient refused the pro-
posed radiation treatment. Th e patient died on January 
26, 2012.
Case Report 2
Th e patient M. A., a 59-year-old female, was ad-
mitted to the Clinical Department of Maxillofacial 
Fig. 1. Mucosal melanoma of the upper lip.
Fig. 2. Clinical appearance of a tumor on the mucosa 
of the lower lip at the time of patient admission 
to the hospital.
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Surgery, Sarajevo University Hospital Centre, on Sep-
tember 29, 2014, for extensive tumorous changes in 
the region of the lower lip. Th e changes had been pres-
ent for several years as a small red nodule on the mu-
cosa of the lower lip, with gradual growth (Fig. 2). Th e 
patient was a long-term neuropsychiatric patient with 
the diagnosis of schizophrenia. Her therapy included 
Haldol 2x2 mg, Trazem 1x1, Prazine 1x25 mg, and 
Apaurin when necessary. She denied any hereditary 
diseases. She had allergy to potatoes. She was a non-
smoker, and did not consume alcohol. Clinical exami-
nation verifi ed a change of 5x5 cm in diameter, with 
nodular appearance, red color, covered with necrotic 
deposits, fi xed by a narrower base to the red part of the 
lower lip and its mucosa, pulling the complete lower 
lip backwards. Surgical excision in the ‘W’ pattern was 
performed. Th e histopathology results indicated a 
nodular type malignant melanoma (Breslow c. 40 mm, 
Clark V, pT4b NxMx). At the time of histopathology 
report, the neck on the left side was clinically and by 
use of ultrasound positive. Cervical lymphadenectomy 
was performed on February 9, 2015, with supraomo-
hyoid neck dissection on the right and radical neck 
dissection on the left side. Th e histopathology results 
showed the presence of metastatic lymph nodes in the 
left side of the neck and chronic reactive lymphadeni-
tis on the right side of the neck. Th e patient was re-
ferred to oncology for conservative treatment accord-
ing to the protocol for malignant melanomas. Cur-
rently, radiation treatment is under way.
Discussion
Th e incidence of cutaneous melanoma increased 
dramatically in the second half of the 20th century, in 
contrast to the incidence of melanomas of oral mucosa, 
which has remained stable. In a review article, Chang et 
al. analyzed 84,836 cases of melanoma (in the USA) 
recorded in the period from 1985 to 1994 and localized 
in the skin (91.2%), eyes (5.2%), mucosa (1.2%), and 
unknown primary localization (2.2%) (Table 1)26. In the 
study by Cheung et al., there were 659 cases of mela-
noma of the gastrointestinal tract: 53.6% anorectal (anal 
31.4%, and rectal 22.2%), 32.8% oropharyngeal, 5.9% 
esophageal, 2.7% of the stomach, 2.3% of the small in-
testine, 1.4% of the gallbladder, and 0.9% of the colon27.
In the review article by Hicks and Flaitz, aggre-
gated data are given from several articles related to 
melanomas of the mucosa of the head and neck, which 
include 703 cases of oral mucosa and 770 cases of si-
nonasal mucosa (Table 2)4,26,27. In the review article by 
Mihajlović et al.36, data are cited from the American 
literature that OM are rare tumors with an annual in-
cidence of 0.2 per million, that is, 1 case per 5 million 
people37. Th e authors from South America provide a 
fi gure of 1.2 OM cases per 10 million38. OMs are more 
common in the Japanese population, accounting for 
7.5% of all melanomas. Skin melanomas in Japan have 
a lower incidence than in the USA17,39.
Table 1. Melanoma cases registered in the USA 












Unknown primary location 2.2 1,952
Regional metastasis 43.0
Distant metastasis 57.0




Hard palate 66 9
Soft palate 7 1
Gingiva 37 5
Maxillary gingiva 114 16
Mandibular gingiva 50 7
Oral cavity 82 12
Buccal mucosa 46 6
Lips 45 6
Tongue 18 3
Base of the mouth 11 2
Uvula 4 <1
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In the Republic of Croatia, no separate records are 
kept of melanomas of the oral mucosa40. In the Fed-
eration of Bosnia and Herzegovina, no records are 
kept of melanomas of the oral mucosa either, but re-
cords are kept of topographic diagnoses of oral carci-
nomas of the lips, tongue, mouth, salivary glands, ton-
sils and oropharynx41.
Th e prognosis of OM is poor, the 5-year survival is 
between 10% and 25%, and the average survival is less 
than 2 years. For example, the 5-year survival in pa-
tients with positive cervical lymph nodes is 16.4% and 
in patients with negative cervical lymph node fi ndings 
38.7%8. OM more often aff ects men than women 
(2:1). In men, it occurs one decade earlier than in 
women. In men, it occurs most often in the decade 
from 51 to 60 years of age, and in women between 61 
and 70 years of age8.
Conclusion
Primary melanomas of the oral mucosa are a very 
rare and aggressive malignancy. OM occurs from the 
existing melanin pigmentation, but some develop de 
novo. Dentists and family physicians, when examining 
pigmented oral mucosal lesions, should suspect OM in 
their diff erential diagnosis. Th erefore, in every patient 
with oral pigmentation, oral biopsy specimen should 
be obtained as a diagnosis based solely on clinical ap-
pearance may be insuffi  cient. Histopathologic diagno-
sis is the gold standard in the diagnosis of melanomas. 
About 80% of OMs are located in the region of the 
mucosa of the palate and maxillary gingiva.
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Sažetak
MELANOM ORALNIH SLUZNICA – DVA PRIKAZA SLUČAJA I PREGLED LITERATURE
B. Topić, T. Mašić, S. Radović, I. Lincender i E. Muhić
Oralni melanom (OM) nastaje iz aktiviranih ili genski izmijenjenih epidermnih melanocita. Nema znanstvenih dokaza 
da se OM može vezati za fi zikalne, kemijske i termičke iritacije ili druge rizične čimbenike usne šupljine. Prema podacima iz 
različitih zemalja na OM otpada od 0,2% do 7,5% ( Japan) svih slučajeva melanoma kože i sluznica. Odnos muškaraca i žena 
za OM je 2:1. Oko 80% slučajeva OM locirano je na sluznici tvrdog nepca i maksilarne gingive. U ovom radu prikazuju se 
dva slučaja OM gornje i donje usne u osoba ženskog spola u dobi od 62 i 59 godina. Opisane su dijagnoza, diferencijalna 
dijagnoza i terapija.
Ključne riječi: Melanom – patologija; Oralni tumori – dijagnostika; Oralni tumori – terapija; Prikazi slučaja
